AACE In the news

08/31/2026

Updated AACE Guidance on Managing Dyslipidemia in T2D

Dyslipidemia is a major driver of cardiovascular risk in patients with type 2 diabetes (T2D), and lipid management is a key component of the the latest AACE Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes - 2026 Update. Immediate Past President Scott D. Isaacs, MD, FACP, FACE, reviews new recommendations on LDL-C goals and individualized care in this population. Listen to the podcast at ReachMD.com.

8/31/2026 | ReachMD

Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk

For patients with diabetes, effective care requires more than just lowering A1C. Immediate Past President Scott D. Isaacs, MD, FACP, FACE, discusses the importance of incorporating comorbidities into care and strategies for systematic screening and follow-up. Listen to the podcast at ReachMD.com.

08/31/2026 | ReachMD

Hypertension in T2D: Understanding the AACE Recommendations

For patients with type 2 diabetes, the latest AACE Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes - 2026 Update supports tailoring hypertension treatment to individual risk profiles. Immediate Past President Scott D. Isaacs, MD, FACP, FACE, shares updated blood pressure targets, first-line therapies and key management considerations for patients at increased risk. Listen to the podcast at ReachMD.com.

July 28, 2026 | Medscape

Rapid Childhood Weight Gain Predicts Later-Life Metabolic Disease Clusters

A decades-long study shows that excess weight acts as a cumulative exposure shaping lifelong metabolic health, with rapid BMI gain in childhood strongly predicting later-life clusters of hypertension, diabetes, dyslipidemia, and organ dysfunction. AACE President Dace L. Trence, MD, MACE, highlighted the study’s 36-year follow-up and robust cohort, emphasizing, "Weight control is important, even during ages 6 to 18 — typically an age range in which we don’t focus on weight unless obesity or morbid obesity is present."

July 6, 2026 | Healthline

Generic Mounjaro, Zepbound May Be Coming, Rivaling Current GLP-1s

Healthline reports that federal regulators have agreed to review applications for potentially less expensive generic versions of the tirzepatide medications Mounjaro and Zepbound. In the article, AACE President Dace L. Trence, MD, MACE, emphasized that cost remains a major barrier to starting and continuing these medications, and noted their potential benefits for blood pressure, cholesterol, and cardiovascular risk.

July 1, 2026 | NPR News

Medicare Offers Access to Popular Obesity Medications for $50 a Month

Medicare is offering beneficiaries access to popular obesity medications for a $50 monthly copay, with certain eligibility criteria and a temporary measure that runs through 2027. In an NPR report, AACE President Dace L. Trence, MD, MACE, explained that the Medicare Bridge program may expand access to obesity medications for eligible beneficiaries, while noting that not all Medicare patients will qualify and prior authorization may create challenges. Read the full article on NPR News to learn more.

May 4, 2026 | AACE Media

AACE 2026 Annual Meeting Media Coverage

Our 2026 Annual Meeting in Las Vegas attracted significant media attention, highlighting our dedication to advancing the field of clinical endocrinology. Explore 25 national press articles showcasing key insights, groundbreaking research, and innovative treatments presented during our event.

April 21, 2026 | AARP

7 Things Constipation Can Tell You About Your Health

New or unexplained constipation in your 50s or later can signal serious conditions, including colorectal cancer. AACE President Dace L. Trence, MD, MACE, explains that constipation may also be linked to endocrine conditions, particularly hypothyroidism and diabetes. Read the full article on AARP to learn more.

April 17, 2026 | Medscape

Upcoming AACE Meeting Theme in Las Vegas: ‘Viva Nutrition!’

The theme of the upcoming American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas is "Viva Nutrition! Advancing Endocrine Practice From the Inside Out." AACE President Dace L. Trence, MD, MACE, and Annual Meeting Chair Rifka Schulman-Rosenbaum, MD, FACE, share highlights of upcoming sessions and key clinical pearls.

April 6, 2026 | Endocrine Today

Diabetes Classifications, New Medications Focus of 2026 AACE Type 2 Diabetes Algorithm

Learn about the key updates in the 2026 AACE Type 2 Diabetes Algorithm, including a new diabetes classification tool and the recognition of MASLD as a comorbidity for the first time. AACE Task Force Chair Susan L. Samson, MD, PhD, FRCPC, FACE, and Vice Chair Priyathama Vellanki, MD, share insights on the latest evidence, therapies, and clinical considerations shaping patient care.

March 23, 2026 | Doc Wire News

Type 2 Diabetes Care in 2026: Inside the New AACE Algorithm

The first AACE diabetes management algorithm was introduced in 2009, and the new 2026 AACE Algorithm for Management of Adults With Type 2 Diabetes moves into the era of modern, evidence-based, complications-focused care rather than glucose alone. As a member of the writing group, AACE Past President Scott D. Isaacs, MD, FACP, FACE, explains what has changed, why it matters now, and how clinicians can start applying these updates in everyday practice.

March 17, 2026 | Endocrinology Advisor

AACE Releases 2026 Update to Type 2 Diabetes Management Algorithm

The American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Management of Adults with Type 2 Diabetes - 2026 Update provides evidence-based visual guidance and key considerations for the diagnosis and management of adults with prediabetes and diabetes. Learn about the key updates from Task Force Chair Susan L. Samson, MD, PhD, FRCPC, FACE, and Vice Chair Priyathama Vellanki, MD, in an article with Endocrinology Advisor.

February 25, 2026 | Everyday Health

Why Blood Sugar Matters for Heart Health Even if You Don’t Have Diabetes

If your blood sugar is on the rise, it’s not just a diabetes risk. AACE President Dace L. Trence, MD, MACE, emphasizes that prediabetes can raise cardiovascular risk by driving inflammation and oxidative stress that damage blood vessels, and that bringing blood sugar down is linked with better cardiovascular outcomes. Learn more by reading the full article on Everyday Health.

February 23, 2025 | Everyday Health

Why Blood Sugar Is Harder to Control During Illness, Injury, or Recovery

Even if your blood sugar is usually well managed, unexpected fluctuations can happen during illness, injury, or recovery, especially when your immune system is under stress. AACE Past President Scott D. Isaacs, MD, FACP, FACE, explains that during these times, your body temporarily prioritizes survival over perfect glucose control, even if you normally have very stable numbers. Read the Everyday Health article for practical strategies to help stabilize blood sugar.

January 6, 2026 | NPR News

Wegovy Pill Now Available at Pharmacies

The weight loss medication Wegovy is now available as a pill. In an NPR report, AACE Past President Scott D. Isaacs, MD, FACP, FACE, emphasizes the importance of careful patient education, noting that the medication must be taken exactly as directed to be effective. Listen to the full interview on NPR News.

January 2, 2026 | Doc Wire News

Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes With Superior Metabolic and Renal Benefits in Type 2 Diabetes

The long‑awaited results of SURPASS‑CVOT were recently published in the New England Journal of Medicine, marking a major advance in the evidence base for incretin‑based therapy for patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). AACE Past President Scott D. Isaacs, MD, FACP, FACE, highlights that this was the first randomized, prospective cardiovascular outcomes trial to show that tirzepatide delivers cardiovascular benefits that extend beyond glycemic control and weight reduction in a high‑risk secondary‑prevention population. Read the full article on Doc Wire News to learn more.

December 23, 2025 | Healio

FDA Approves Wegovy Pill, the First Oral GLP-1 to Treat Obesity

Following FDA approval of the first oral GLP-1 for obesity, AACE President Scott D. Isaacs, MD, FACP, FACE, called the Wegovy pill one of the most important developments in endocrinology in 2025, noting that an oral option expands access to effective obesity treatment while requiring careful attention to dosing and tolerability. Learn more by reading the full article on Healio.

December 23, 2025 | Medscape

Turning the Tide in Type 2 Diabetes: Evidence-Based Pathways to Remission

In a Medscape review on type 2 diabetes remission, AACE President Scott D. Isaacs, MD, FACP, FACE, emphasized that remission is not the same as reversal and highlighted growing evidence that sustained lifestyle changes and modern therapies, including GLP-1 receptor agonists, can help some patients achieve and maintain remission with ongoing monitoring.

December 16, 2025 | Everyday Health

Reversing Prediabetes Could Slash Heart Disease Risk

According to new research, people with prediabetes who lower blood sugar to normal levels cut their heart disease risk in half. AACE President Scott D. Isaacs, MD, FACP, FACE, highlights that achieving prediabetes remission through structured lifestyle changes can significantly reduce the risk of heart attack and heart failure. The findings reinforce the importance of knowing your exact numbers and working with a clinician to normalize glucose as a measurable, meaningful goal for long-term cardiovascular health.

December 3, 20205 | Medscape

Hearing Loss: A Silent Complication of Diabetes

A new review published in Otolaryngology-Head and Neck Surgery reports that individuals with type 2 diabetes face a significantly elevated risk of hearing loss, particularly at higher frequencies. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that adults with diabetes have an increased risk of hearing loss because high blood sugar damages the small blood vessels that supply the inner ear, leading to poor blood flow and nutrient delivery, which causes the delicate hair cells of the cochlea to deteriorate and results in sensorineural hearing loss, especially at higher frequencies. An important take-home message of the study is that hearing loss should be recognized as a microvascular complication of diabetes, for which screening and early detection are warranted as part of comprehensive diabetes care. Learn more by reading the full article on Medscape.